Skip to main content
Prime Medicine, Inc. logo

Prime Medicine, Inc. — Investor Relations & Filings

Ticker · PRME ISIN · US74168J1016 US Manufacturing
Open in API
Filings indexed 259 across all filing types
Latest filing 2024-11-12 Interim / Quarterly Rep…
Country US United States of America
Listing US PRME

About Prime Medicine, Inc.

https://primemedicine.com/

Prime Medicine, Inc. is a biotechnology company focused on developing a new class of one-time, curative genetic therapies. The company's approach is centered on its proprietary Prime Editing platform, a next-generation gene editing technology. Prime Editing is designed to function like a precise 'search and replace' mechanism for the genome, capable of correcting a wide range of disease-causing genetic mutations. It can perform insertions, deletions, and all types of point mutations without inducing double-strand DNA breaks, a key differentiator from some earlier gene editing techniques. The company's mission is to address the root genetic cause of debilitating diseases, aiming to provide patients with potentially lifelong therapeutic benefits.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q3 2024
2024-11-12 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 12, 2024, by Prime Medicine, Inc. It specifically states in Item 2.02 that the company issued a press release announcing financial results and business highlights for the quarter ended September 30, 2024. The document includes a press release as Exhibit 99.1 but does not contain the full financial statements or detailed financial analysis itself. The length of the document is 3731 characters, which is relatively short and consistent with a current report or earnings release announcement rather than a full quarterly or annual report. The document is a Current Report (Form 8-K) primarily announcing quarterly financial results, which aligns with the definition of an Earnings Release (ER) as an initial announcement of quarterly/periodical financial results with key highlights only. Therefore, the appropriate classification is Earnings Release (ER).
2024-11-12 English
Major Shareholding Notification 2024
Major Shareholding Notification
2024-11-12 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated October 24, 2024. It includes a Regulation FD Disclosure about a press release issued by the company regarding preclinical advances and a scientific congress presentation. The document is short (3785 characters) and primarily furnishes a press release as Exhibit 99.1. There are no financial statements or detailed financial data included. The document states that the information is "furnished" and not "filed," indicating it is an announcement rather than a full report. This fits the profile of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not fit into other specific categories such as Annual Report, Earnings Release, or Investor Presentation. Therefore, the appropriate classification is Regulatory Filings (RNS).
2024-10-24 English
FORM 4
Director's Dealing
2024-10-10 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated September 28, 2024, which is a Current Report pursuant to the Securities Exchange Act of 1934. The content describes the entry into a material definitive agreement, specifically a Research Collaboration and License Agreement and a Securities Purchase Agreement with Bristol-Myers Squibb Company. It also includes information about unregistered sales of equity securities and Regulation FD disclosures including press releases and a corporate presentation. The document does not contain comprehensive financial statements or detailed financial performance data but rather announces significant corporate events and agreements. Form 8-K filings are current reports used to announce major events and are best classified under Regulatory Filings (RNS) as they do not fit the definitions of other specific report types such as Annual Report, Earnings Release, or Capital/Financing Update. Therefore, the appropriate classification is Regulatory Filings (RNS).
2024-09-30 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.